Cancer therapeutic - AstraZeneca/Sarah Cannon Research Institute
Latest Information Update: 17 Apr 2012
At a glance
- Originator AstraZeneca; Sarah Cannon Research Institute
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 23 Nov 2010 Clinical trials in Cancer in USA (unspecified route)